Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

Related Clinical Trial
Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

Official Title

An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers

Brief Summary

      Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some
      neuroprotective activities and it is hoped that they could be helpful for people with
      neurodegenerative illnesses such as progressive supranuclear palsy (PSP).

      The purpose of this study is to find out whether the nutritional supplement alpha-lipoic
      acid/L-acetyl carnitine is safe and well-tolerated in individuals with PSP when given daily,
      and whether it affects their well-being, brain scan measurements and blood tests that measure
      the energy metabolism in cells.
    

Detailed Description

      Multiple lines of evidence support mitochondrial dysfunction and oxidative stress playing a
      role in the pathogenesis of atypical Parkinsonism, including PSP. Such dysfunction may well
      contribute to the tau pathology that is well-recognized in PSP, thus providing a link between
      the two processes. This pathway therefore represents an excellent potential target for novel
      therapeutic intervention in neurodegenerative disorders, and a number of well-tolerated and
      safe nutritional supplements have been identified that appear to augment mitochondrial
      function, and improve oxidative stress.

      Alpha-lipoic acid and L-acetyl carnitine are two nutritional supplements that have received
      increasing attention as potential neuroprotective interventions in neurodegenerative and
      other disease states. Alpha-lipoic acid/L-acetyl carnitine had been demonstrated to improve
      learning in aged beagles over 2 months of administration, and showed a trend to improve
      cognitive function in a mouse model of Alzheimer's disease (human apoE4 transgene). Moreover,
      alpha-lipoic acid/L-acetyl carnitine was neuroprotective in a mouse model of Parkinson's
      disease (rotenone-induced parkinsonism), with effects including decreased oxidative stress,
      and increased mitochondrial biogenesis. In fibroblasts derived from individuals with
      Alzheimer's disease, alpha-lipoic acid/L-acetyl carnitine reduced increased levels of
      oxidative stress. In healthy men exposed to intensive exercise, alpha-lipoic acid provided
      antioxidant effects systemically (decreased peroxidation). L-acetyl carnitine improved
      neuroimaging correlates of cerebral blood flow in 30 subjects with dementia. These
      nutritional supplements have been safe and well-tolerated, and they have been tested in age
      groups including children, up to the elderly. Alpha-lipoic acid had been successfully
      administered over an extended period in an open-label trial in Alzheimer's disease.
      Importantly, it appeared that the effects of alpha-lipoic acid and L-acetyl carnitine when
      administered together were significantly augmented (100-1000 times), as opposed to when
      administered separately. This therefore provided a strong rationale to test the two in
      combination.

      In addition to monitoring clinical features, we had also chosen to test physiologic effects
      of alpha-lipoic acid/L-acetyl carnitine in our PSP subjects using two biomarkers that provide
      measures of mitochondrial function and oxidative stress. This was particularly important,
      since both supplements may act by multiple mechanisms. 1H MRSI is a technique that provides
      insight into the metabolism of several endogenous brain compounds, most notably
      N-acetyl-L-aspartate (NAA), choline-containing compounds (Cho), and creatine and
      phosphocreatine (Cr). A number of studies of mitochondrial function had firmly established
      the utility of 1H MRSI in probing potential mitochondrial energy metabolism dysfunction. 31P
      MRSI provided complementary information to probe in vivo mitochondrial energy metabolism and
      tissue energetics. In addition, we proposed using markers of oxidative damage (including
      8-hydroxydeoxyguanosine) as well as metabolomic analysis to test a composite panel of
      quantitative measures in plasma. We used an established metabolomic platform that has proven
      to identify specific combinations of metabolites differing between neurodegenerative disease
      states (including Parkinson's disease, Huntington's disease) and healthy controls. Our
      overall aim was to generate an "oxidative biomarker" and "metabolomic read-out" of the
      peripheral biochemical effects of alpha-lipoic acid/L-acetyl carnitine in PSP.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Adverse Events

Secondary Outcome

 Cerebral Oxidative Stress Markers

Condition

Progressive Supranuclear Palsy

Intervention

alpha-lipoic acid and L-acetyl carnitine

Study Arms / Comparison Groups

 Juvenon
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

11

Start Date

September 14, 2010

Completion Date

April 7, 2015

Primary Completion Date

September 24, 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of probable PSP by NINDS/PSP workshop criteria (see patient folder)

          -  Age 40-75 years

          -  Able to undergo MRI

          -  Absence of significant medical, psychiatric, and other neurological disease

          -  Stable intake of supplements and medication

        Exclusion Criteria:

          -  Failure to meet probable PSP diagnosis by NINDS/PSP workshop criteria

          -  unable to comply with informed consent process

          -  unable to undergo MRI

          -  presence of significant medical, psychiatric (incl MDD) or other neurological (incl
             epilepsy, brain tumor, stroke) disease

          -  possibility of pregnancy (negative test required in women of childbearing age)
      

Gender

All

Ages

40 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Claire Henchcliffe, MD DPhil, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01537549

Organization ID

IRB1006011088


Responsible Party

Sponsor

Study Sponsor

Weill Medical College of Cornell University


Study Sponsor

Claire Henchcliffe, MD DPhil, Principal Investigator, Weill Medical College of Cornell University


Verification Date

April 2017